Hollywood Push for Dewormers: Cancer Patients Flock!

Scientists working in a laboratory with test tubes

A Hollywood podcast story and a livestock dewormer have quietly pushed thousands of desperate cancer patients toward an unproven treatment the medical establishment long tried to keep at the margins.

Story Snapshot

Prescriptions for ivermectin and related antiparasitic drugs surged after Mel Gibson shared stage‑four cancer anecdotes on Joe Rogan’s show.
Laboratory studies show ivermectin can kill or weaken cancer cells, but doctors say human evidence is still thin.
Federal cancer researchers are now running formal trials even as many experts and media outlets urge strong caution.
The clash over ivermectin reflects a deeper trust crisis after years of medical groupthink, censorship, and politicized science.

How a Podcast Anecdote Sparked a Rush for Dewormer Pills

Researchers at the University of California, Los Angeles examined prescribing data before and after actor Mel Gibson appeared on “The Joe Rogan Experience” in January 2025 and described three friends with stage‑four cancer who he said recovered after taking ivermectin and another antiparasitic drug, fenbendazole. Within months, prescriptions for the ivermectin‑benzimidazole combination more than doubled overall, and increased more than two and a half times among cancer patients, with the biggest spike in the American South.

A separate analysis of oncology practice patterns found that interest in ivermectin and fenbendazole “has spread like wildfire,” with patients on conventional chemotherapy asking to add these drugs as supplemental therapy rather than full replacements. Oncologists report that many patients arrive already influenced by online testimonies, podcast clips, and word‑of‑mouth stories about miraculous remissions, and are often skeptical when doctors push back. The pattern mirrors the earlier pandemic battles over off‑label ivermectin, only this time the stakes involve advanced cancers.

What the Science Really Shows So Far on Ivermectin and Cancer

Peer‑reviewed laboratory work confirms that ivermectin can damage cancer cells in test tubes and animal models. A major scientific review describes “powerful antitumor effects,” including inhibition of proliferation, metastasis, and new blood vessel growth in a wide range of cancer cell lines, along with triggering apoptosis and other forms of programmed cell death.^[3] These effects appear tied to ivermectin’s ability to interfere with cancer‑related signaling pathways such as Wnt/β‑catenin and Akt/mTOR, and to target a protein called p‑21‑activated kinase 1.^[3]

Because of these signals, the National Cancer Institute and other researchers have launched early‑stage clinical trials. One government‑listed study is testing ivermectin together with the immunotherapy drug pembrolizumab in patients with metastatic triple‑negative breast cancer, exploring whether ivermectin can help the immune system attack tumors more effectively.^[4] Another trial program is evaluating ivermectin in combination with newer immune checkpoint inhibitors in advanced cancers, focusing first on safety and dosage before any claim of benefit. At the same time, a 2024 medical review stresses that, despite extensive lab work, there are still no large randomized trials proving a survival advantage in humans.^[1]

Why Oncologists Warn Against Substituting Dewormers for Proven Therapies

Pediatric cancer experts at the Children’s Hospital of Philadelphia point out that existing ivermectin cancer research has been limited to cells and animals, not people, and that “there are a few studies that show ivermectin could help slow cancer growth, but those studies were done in labs or in animals – not in humans.”^[5] The American Cancer Society similarly warns that fenbendazole, the animal dewormer often paired with ivermectin online, has not been properly tested in humans as a cancer treatment and should not be viewed as a proven therapy.

Oncology organizations emphasize two major dangers. First, patients may delay or skip evidence‑based treatments in favor of internet protocols built from anecdotes and pet‑medicine dosing charts. Second, unsupervised use can cause drug interactions or organ stress when layered on top of already intense chemotherapy regimens. Cancer communication groups note that repurposed drugs like ivermectin and fenbendazole remain experimental: some small studies suggest they might enhance standard therapies, but any real benefit must be proved in controlled human trials, not on social media.

A Deeper Fight Over Trust, Censorship, and Who Owns “Science”

For many families facing terminal cancer, the surge in ivermectin use is less about conspiracy theories and more about survival. Patients have watched decades of expensive, marginally effective cancer regimens, seen public health authorities get major calls wrong during the pandemic, and noticed how quickly dissenting voices were branded “misinformation.” Some now view low‑cost generics like ivermectin as potential lifelines that bureaucracies and pharmaceutical interests were too slow or too arrogant to examine seriously.^[1]

Prescriptions for ivermectin and benzimidazole among cancer patients rose 2.5X after actor Mel Gibson endorsed the unproven treatment on Joe Rogan’s podcast, per a JAMA Network Open study. https://t.co/iQcosKJXt7

— Global Health NOW (@ghn_news) May 14, 2026

Federal cancer researchers under the current administration are at least doing one thing right: allowing ivermectin to be studied in structured trials instead of trying to banish it from the conversation.^[4] The responsible, conservative approach is neither blind faith in miracle‑cure anecdotes nor blind obedience to institutions that once pushed one‑size‑fits‑all mandates. Cancer patients deserve transparent data, freedom to discuss off‑label options with trusted doctors, and a medical culture that welcomes tough questions instead of silencing them.